when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

ELI LILLY CO · news · pharmadog

← back to ELI LILLY CO

News mentioning ELI LILLY CO

630 stories

Jul 30, 26AtaiBeckley attracted co-development and royalty offers before $2.8B Lilly dealendpoints

Jul 30, 26Gerresheimer divests two businesses worth €1.5B; Resilience, Lilly boost injectable pen capacityendpoints

Jul 30, 26J&J secures right to take the helm in up to $925M Sail CAR T pactbiospace

Jul 30, 26BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this yearfiercebiotech

Jul 30, 26Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the storebiospace

Jul 30, 26J&J pays Sail $785M, charting course to possible in vivo CAR-T buyoutfiercebiotech

Jul 29, 26FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s databiopharma dive

Jul 29, 26STAT+: Pharmalittle: We’re reading about a fugitive who became a biotech exec, a hospital suing Lilly, and morestat

Jul 29, 26Novo ordered to face CagriSema fraud claims from shareholders: New Jersey courtbiospace

Jul 29, 26Biotechs bring big launches and pharma rivalries into Q2 earnings periodbiospace

Jul 28, 26FDA offers updated guidance for generics of weight loss blockbustersendpoints

Jul 28, 26Eli Lilly tops new biopharma ranking on launch success, development speedfiercebiotech

Jul 28, 26Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage studybiospace

Jul 28, 26Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder winfiercebiotech

Jul 28, 26As pharma descends on China for deals, BIOSECURE Act raises intellectual property riskbiospace

Jul 27, 26Argenx deepens immuno expertise with $2.2B Forte Biosciences buybiospace

Jul 27, 26Apnimed aspires for up to $160M IPO as sleep apnea pill launch nearsfiercebiotech

Jul 27, 26Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdlebiospace

Jul 27, 26Summit, Merck must navigate new regulatory terrain in China-first cancer landscapebiospace

Jul 24, 26Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotechbiospace

Jul 24, 26Novo asks court to block Lilly ads; Merck strikes HIV PrEP dealendpoints

Jul 24, 26Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myelomabiopharma dive

Jul 24, 26Lilly’s $3.8B psychedelics bet won’t open the M&A floodgatesbiospace

Jul 24, 26Summit has less than a year of cash runway left as PD-1/VEGF verdict nearsbiospace

Jul 23, 26Chutes & Ladders—Biogen R&D vet gets in Formationfiercebiotech

Jul 23, 26STAT+: European regulators take steps to bolster clinical trial transparencystat

Jul 23, 26Lilly, with new data, to seek FDA approval of obesity drug retatrutidebiopharma dive

Jul 23, 26FDA panel confronting peptide controversystat

Jul 23, 26A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribingstat

Jul 23, 26BeOne commits $300M to US manufacturing expansion, creating 120 new jobsbiospace

← prevpage 14 of 21next →